This is the authors' abstract. We don't add key points for this paper.
This study correlates the neuroendocrine (NE) markers neuron-specific enolase (NSE), chromogranin A (CGA), and synaptophysin (SYN) with the therapeutic responses and the survival times of patients with non-resectable non-small cell lung cancer (NSCLC). One hundred twenty-six patients (male 64%, female 36%) with histopathologically confirmed NSCLC, treated with combination chemotherapy and radiotherapy in 1 center, underwent immunohistochemical analyses. Thirty-nine patients (31%) were positive for NSE, 24 (19%) for Chr A, and 27 (21%) for SYN. Favorable therapeutic responses (partial and complete responses [CR]) were significantly greater in patients expressing NSE, Chr A, and SYN (P<0.05). There was a significant correlation between the therapeutic response and the percentage of NE-positive tumor cells (P<0.05). Tumors with greater than 25.5% NSE-positive cells can be predicted to have a favorable therapeutic response (94% sensitivity, 100% specificity). Patients with multiple markers were also more likely to have a favorable response compared to those with only 1 marker (59% compared with 38%) (P<0.05). Those with positive NE expression had significantly better 1- and 2-year survival compared with non-expressers (60% compared with 18%, P<0.001, and 33% compared with 0% P=0.000, respectively). Patients expressing the NE markers NSE, Chr A, and SYN, and those with a larger proportion of positive tumor cells have better therapeutic responses and longer survival times.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Petrovic et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: